IP Library Granted Patent US 8,735,086
Granted Patent B2
US 8,735,086 · App. 13/539,154 · Granted May 27, 2014

Kit for measuring the thrombin generation in a sample of a patient's blood or plasma

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,735,086
App. No.
13/539,154
Granted
May 27, 2014
Kind
B2
Abstract

The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl 2 . The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.

Claims (13)

1. A method for measuring the thrombin generation in whole blood or plasma, comprising the steps of:

(a) providing a lyophilized tissue factor (TF)/phospholipid (PL)-complex and a lyophilized mixture that is dissolvable in water and contains a thrombin-substrate comprising a fluorescent label and CaCl 2 ;

(b) mixing said lyophilized TF/PL-complex and said lyophilized mixture containing thrombin-substrate and CaCl 2 in an amount of plasma or whole blood sample that provides a concentration of 1 mM thrombin substrate and 15 mM CaCl 2 , wherein the lyophilized TF/PL-complex and the lyophilized mixture containing the thrombin-substrate and CaCl 2 are immobilized on a solid support; and

(c) measuring the thrombin generation in said sample.

2. The method according to claim 1 , wherein the sample is a cell-free plasma sample.

3. The method of claim 1 , wherein the thrombin substrate is Z-Gly-Gly-Arg-AMC.

4. The method of claim 1 , wherein the concentration of TF in the lyophilized TF/PL-complex ranges from about 5 to about 1000 pM.

5. The method of claim 1 , wherein the concentration of PL in the lyophilized TF/PL-complex ranges from about 1 to about 100 μM.

6. The method of claim 1 , wherein the TF is of recombinant origin.

7. The method of claim 1 , wherein the PL is a mixture comprising phosphatidylserine (PS) and phosphatidylcholine (PC); or a mixture comprising PS, PC, and phosphatidylethanolamine (PE).

8. The method of claim 1 , wherein the PL is a mixture of PS and PC, and the weight ratio of PC/PS is in the range of from about 60/40 to about 95/5 based on the total amount of phospholipid.

9. The method of claim 1 , wherein the PL is a mixture of PS, PC, and PE, and the weight ratio of PC/PS/PE is in the range of from about 60/20/20 to about 78/17/5, based on the total amount of phospholipids.

10. The method of claim 1 , wherein the solid support is the inner surface of a well of a microtiter plate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036357 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT FROM BAXTER HEALTHCARE SA TO BAXALTA GMBH AND BAXALTA INCORPORATED. Recorded Aug 21, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036412/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036357/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036366/0517 →